JD Health (京东健康) Is No Longer Alibaba Health's (阿里健康) Rival

The Split

Rivalry? Not anymore. Once the go-to comparison in China’s online healthcare, JD Health (京东健康) and Alibaba Health (阿里健康) have diverged so sharply that their contest no longer sits on the same field. According to Chinese outlet TMTPost, citing company filings, both businesses are firmly profitable—JD Health reportedly earned RMB 6.53 billion (about USD 0.9 billion) in 2025 net profit, while Alibaba Health posted RMB 1.36 billion (about USD 0.19 billion) in profit for the first half of fiscal 2026. Each was incubated by an e-commerce giant and listed in Hong Kong, but their operational DNA has now pulled them in opposite directions: JD Health is building assets offline; Alibaba Health is doubling down on platforms and data infrastructure.

JD Health’s Hard Pivot Offline

JD Health has gone from “internet pharmacy” to heavy-asset operator. Reportedly, it ended 2025 with more than 300 self-run pharmacy stores, backed by 22 dedicated pharmaceutical warehouses and over 500 non-pharma warehouses, and has pushed aggressively into bricks-and-mortar health services—from hearing centers and physical checkup clinics to a traditional Chinese medicine hall. It has also scaled in-home care: TMTPost reports over 21,000 nurses now provide at-home blood draws, wound care, and rapid testing across dozens of cities, with “to-home” diagnostics orders up 81.9% year over year. The price of this footprint? Fulfillment expenses rose from RMB 1.99 billion in 2020 to RMB 7.62 billion in 2025, while annual revenue reached RMB 73.4 billion with 217 million active users, according to the same report.

Alibaba Health’s Platform-First Play

Alibaba Health, by contrast, is staying light. Management frames the strategy around “cloud infrastructure,” a “cloud pharmacy,” and a “cloud hospital”—language that matches Alibaba Group’s (阿里巴巴) platform-and-ecosystem ethos. Its “Ma Shang Fangxin” (码上放心) traceability system reportedly works with 900+ major drugmakers, expanding into medical devices and traditional medicine ingredients while layering SaaS analytics on top of anti-counterfeit codes. On the consumer side, Alibaba Health emphasizes SKU scale and marketplace leverage: TMTPost cites 97 million SKUs and 56,000+ merchants on Tmall Health. In AI, it is targeting “serious medicine” use cases—clinical decision support and literature-based evidence retrieval—aiming to reduce hallucinations before large-scale deployment. Headcount tells the story: roughly 1,357 employees at Alibaba Health versus 5,263 at JD Health, per the report.

Why It Matters

The divergence mirrors parent-company genes—JD.com (京东) prizes end-to-end supply chain control and heavy fulfillment; Alibaba favors platform economics and technical enablement. As a result, JD Health now competes more with offline pharmacy chains like Yifeng (益丰) and Dashenlin (大参林), national checkup networks, and heavy-fulfillment players such as Meituan’s (美团) on-demand pharmacy service. Alibaba Health’s battleground is digital health infrastructure and AI, up against healthcare IT firms and model developers vying to define China’s data and workflow standards. Policy and geopolitics loom in the background: China’s tight rules on medical data and online drug sales shape these models, while U.S. export controls on advanced chips could complicate AI training. The headline? JD Health has turned into an omnichannel medical retail-and-services operator; Alibaba Health is positioning as the sector’s operating system. Different arenas, different rivals—and no longer direct opponents.